Rules and Regulations. Notice; extension of the comment period

Agency: Food and Drug Administration, HHS
Action: Notice; extension of the comment period
Citation: FR Doc. 01-24161 · Docket No. 97D-0318

Summary

The Food and Drug Administration (FDA) previously requested that comments on the draft entitled “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products” dated August 2001 be submitted by September 28, 2001, to ensure their adequate consideration in preparation of the final document (66 FR 45683, August 29, 2001). The agency has determined that it will have adequate time to consider, in preparation of the final guidance, comments received by October 28, 2001. FDA is taking this action in response to a request that the agency allow interested parties additional time to review and to submit comments.

Dates

Submit written or electronic comments on the draft guidance to ensure their adequate consideration in preparation of the final document by October 28, 2001. General comments on agency guidance documents are welcome at any time.

Supplementary Information

I. Background In the Federal Register of August 29, 2001 (66 FR 45683), FDA published a notice announcing the availability of a draft guidance document entitled “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products.” The draft guidance document provides comprehensive current recommendations to all registered blood and plasma establishments for deferral of donors with possible exposure to the agent of vCJD. The agency asked interested persons to submit written or electronic comments on the draft guidance to ensure their adequate consideration in preparation of the final document by September 28, 2001. On September 19, 2001, a comment from America's Blood Centers was submitted to the docket requesting that FDA consider comments received after September 28, 2001. The comment stated that blood establishment obligations related to the recent terrorist attack has delayed the review of the guidance by a number of blood establishments. The agency has determined that it will have adequate time to consider comments received by October 28, 2001. II. Comments Interested persons should submit to the Dockets Management Branch (address above) written or electronic comments regarding the draft guidance document by October 28, 2001, to ensure consideration of comments in FDA's preparation of a final guidance. Two copies of any comments are to be submitted, except individuals may submit one copy. Comments should be identified with the docket number found in the brackets in the heading of this document. A copy of the document and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. III. Electronic Access Persons with access to the Internet may obtain the document at either http://www.fda.gov/cber/guidelines.htm or http://www.fda.gov/ohrms/dockets/default.htm. Dated: September 21, 2001. Margaret M. Dotzel, Associate Commissioner for Policy. [FR Doc. 01-24161 Filed 9-26-01; 8:45 am]